Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?
Building a portfolio that can stand the test of time is no easy task. Only a handful of individual stocks are truly capable of outperforming low-cost index funds over long periods of time. After all, the U.S. stock market is a fairly efficient machine.
Companies that steadily grow revenue and earnings over time tend to be rewarded with premium valuations, and vice-versa. As a result, it can be a serious challenge to spot hidden gems in today's market.
Acadia Pharmaceuticals (NASDAQ: ACAD), a commercial-stage biopharma specializing in treatments for central nervous disorders, is a potential market-beating play. Over the past five years, the biotech's shares have soundly outperformed the broader markets. And this year, Acadia's shares have continued their winning ways by rocketing by more than 90% year to date.
Source Fool.com
